Culture of Cervical Carcinoma Tumor Cell Lines

Stern, Peter L.; West, Catherine; Burt, Deborah J.

doi:10.1002/0471722782.ch8

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…>10 spots/10 5 was considered a significant response and are indicated in bold. 47,42,43,43 with FI about 1 with the other peptides showing lower binding in this assay with F1 less than 0.5.…”

Section: Identification Of Potential Hla-a*0201 Binding Peptides Frommentioning

confidence: 70%

“…To do this and confirm that these epitopes are endogenously processed and expressed by tumor cells, we used a naturally 5T4 expressing cervical cancer cell line 778, which does not express HLA-A*0201 or 778A2 where this defect has been rescued by transduction of the HLA-A2 gene. 42 Effector CD8 T cells generated in vitro by stimulating with peptide-pulsed DC were tested for the capacity to recognize 5T4 positive 778 HLA-A2 positive or negative tumor cells. We found that 5T4 peptide 40 and 41 activated T cells recognized 5T4 positive tumor cells only if they expressed HLA-A*0201 (778 A21 cell line) as judged by their IFNg production detected by both ELISPOT (Fig.…”

Section: Cd8 T Cells Specific For Putative 5t4 Hla-a*0201-restricted mentioning

confidence: 99%

See 1 more Smart Citation

Cd8 T‐cell recognition of human 5T4 oncofetal antigen

Smyth

Elkord

Taher

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

The 5T4 oncofetal antigen is expressed by a wide variety of human carcinomas, including colorectal, ovarian and gastric carcinomas. The restricted expression of 5T4 on tumor tissues as well as its implication in tumor progression and bad prognosis makes 5T4 a promising new candidate for immunotherapy. An MVA vaccine encoding 5T4 antigen has been successfully evaluated in preclinical studies in a murine tumor model. Here, we report the generation of human CD8 T cells specific for the 5T4 antigen by stimulation with autologous monocyte derived DC infected with a replication defective adenovirus encoding the 5T4 cDNA (Ad5T4). Analysis of several donors confirms a repertoire of such CD8 responses. In a parallel approach, incorporating the results of proteasome-mediated digestion of 5T4 derived 35-mer peptides and the potential high affinity epitopes predicted by a computer-based algorithm, we identified 8 putative HLA-A*0201-presented CD8 MHC class I epitopes of 5T4 antigen. Two of these generated specific CD8 T cells after restimulation with peptide loaded autologous DC and assay by cytotoxicity and IFNc ELISPOT. Moreover these particular peptide generated T cells recognized naturally 5T4 positive tumor cells only if they expressed HLA-A*0201 as judged by IFNc ELISPOT or ELISA. Also, HLA-A*0201 CD8 T cells recognized these peptides in a DC-Ad5T4 polyclonal response. In conclusion, there is a repertoire of CD8 T cell recognition of 5T4 in normal human donors and some candidate HLA-A*0201 epitopes have been identified. ' 2006 Wiley-Liss, Inc.Key words: 5T4 oncofetal antigen; dendritic cells; adenovirus; proteasome; CD8 T cells There are several types of human tumor-associated antigens (TAAs), which are being exploited as targets for developing immunotherapies against malignant tumors. 1-4 Such antigens include, over or selectively expressed normal molecules (differentiation, oncofetal antigens), viral-and tumor-specific antigens, including mutated products (sometimes functional in the transformed state). Human 5T4 is a 72 kDa cell surface oncofetal antigen defined by a monoclonal antibody raised against wheat germ agglutinin-glycoproteins isolated from human syncytiotrophoblast microvillus plasma membranes. 5,6 The 5T4 antigen is highly expressed in trophoblast, but shows relatively limited expression in other normal tissues. 7 In contrast, the 5T4 antigen is upregulated in a wide variety of human carcinomas, including colorectal, gastric and ovarian carcinomas, where it is associated with poor clinical outcome. [8][9][10][11][12] The restricted expression of 5T4 antigen on tumor tissues as well as its association with tumor progression makes it a promising new candidate for immunotherapy. Several approaches to developing immunotherapies against this target are under development. Thus, we are harnessing the tumor cell surface expression of 5T4, by using antibodies to targeted drugs and/ or activation of effectors 13,14 or retargeting using chimeric immune receptors of polyclonal T-cell populations. 15,16 Our work in...

show abstract

Section: Identification Of Potential Hla-a*0201 Binding Peptides Frommentioning

confidence: 70%

Section: Cd8 T Cells Specific For Putative 5t4 Hla-a*0201-restricted mentioning

confidence: 99%

Cd8 T‐cell recognition of human 5T4 oncofetal antigen

Smyth

Elkord

Taher

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Current Status of Methods to Assess Cancer Drug Resistance

Lippert¹,

Ruoff²,

Volm³

2011

Int. J. Med. Sci.

View full text Add to dashboard Cite

Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, resistance being either preexisting (intrinsic resistance) or induced by the drugs (acquired resistance). At present, resistance is usually diagnosed during treatment after a long period of drug administration.In the present paper, methods for a rapid assessment of drug resistance are described. Three main classes of test procedures can be found in the literature, i.e. fresh tumor cell culture tests, cancer biomarker tests and positron emission tomography (PET) tests. The methods are based on the evaluation of molecular processes, i.e. metabolic activities of cancer cells. Drug resistance can be diagnosed before treatment in-vitro with fresh tumor cell culture tests, and after a short time of treatment in-vivo with PET tests. Cancer biomarker tests, for which great potential has been predicted, are largely still in the development stage. Individual resistance surveillance with tests delivering rapid results signifies progress in cancer therapy management, by providing the possibility to avoid drug therapies that are ineffective and only harmful.

show abstract

Culture of Cervical Carcinoma Tumor Cell Lines

Cited by 2 publications

References 23 publications

Cd8 T‐cell recognition of human 5T4 oncofetal antigen

Cd8 T‐cell recognition of human 5T4 oncofetal antigen

Current Status of Methods to Assess Cancer Drug Resistance

Contact Info

Product

Resources

About